BridgeBio Oncology Therapeutics annual return on equity
2025
BridgeBio Oncology Therapeutics Return on Equity (ROE) Growth & History (BBOT)
BridgeBio Oncology Therapeutics's return on equity was −115.33% for fiscal 2025.
View full BridgeBio Oncology Therapeutics company overviewBridgeBio Oncology Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −115.33% | — |
BridgeBio Oncology Therapeutics quarterly return on equity
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −16.24% | — |
| Q1 2026 | 2026-03-31 | −10.75% | — |
| Q4 2025 | 2025-12-31 | −9.05% | — |
| Q3 2025 | 2025-09-30 | −40.88% | — |
BridgeBio Oncology Therapeutics return on equity trends
The latest reported quarter, Q2 2026, shows −16.24%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review BridgeBio Oncology Therapeutics source filings ↗